Eli Lilly Debt to Equity Ratio 2010-2024 | LLY
Current and historical debt to equity ratio values for Eli Lilly (LLY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Eli Lilly debt/equity for the three months ending September 30, 2024 was 2.03.
| Eli Lilly Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-09-30 |
$61.29B |
$14.32B |
4.28 |
| 2024-06-30 |
$58.24B |
$13.64B |
4.27 |
| 2024-03-31 |
$51.05B |
$12.90B |
3.96 |
| 2023-12-31 |
$53.14B |
$10.86B |
4.89 |
| 2023-09-30 |
$46.61B |
$11.31B |
4.12 |
| 2023-06-30 |
$43.67B |
$11.15B |
3.92 |
| 2023-03-31 |
$41.87B |
$11.30B |
3.71 |
| 2022-12-31 |
$38.71B |
$10.78B |
3.59 |
| 2022-09-30 |
$37.30B |
$10.17B |
3.67 |
| 2022-06-30 |
$38.40B |
$8.66B |
4.44 |
| 2022-03-31 |
$37.46B |
$9.46B |
3.96 |
| 2021-12-31 |
$39.65B |
$9.16B |
4.33 |
| 2021-09-30 |
$40.23B |
$7.95B |
5.06 |
| 2021-06-30 |
$41.15B |
$6.66B |
6.18 |
| 2021-03-31 |
$39.74B |
$7.10B |
5.60 |
| 2020-12-31 |
$40.81B |
$5.83B |
7.01 |
| 2020-09-30 |
$38.95B |
$5.00B |
7.80 |
| 2020-06-30 |
$37.70B |
$4.27B |
8.82 |
| 2020-03-31 |
$37.91B |
$3.20B |
11.86 |
| 2019-12-31 |
$36.59B |
$2.70B |
13.56 |
| 2019-09-30 |
$34.43B |
$3.46B |
9.94 |
| 2019-06-30 |
$35.81B |
$2.86B |
12.53 |
| 2019-03-31 |
$35.44B |
$2.57B |
13.82 |
| 2018-12-31 |
$33.00B |
$10.91B |
3.03 |
| 2018-09-30 |
$30.47B |
$14.15B |
2.15 |
| 2018-06-30 |
$30.74B |
$11.62B |
2.65 |
| 2018-03-31 |
$29.77B |
$14.59B |
2.04 |
| 2017-12-31 |
$33.31B |
$11.67B |
2.86 |
| 2017-09-30 |
$28.05B |
$14.96B |
1.88 |
| 2017-06-30 |
$26.78B |
$14.17B |
1.89 |
| 2017-03-31 |
$23.52B |
$14.10B |
1.67 |
| 2016-12-31 |
$24.73B |
$14.08B |
1.76 |
| 2016-09-30 |
$21.98B |
$15.62B |
1.41 |
| 2016-06-30 |
$21.82B |
$14.66B |
1.49 |
| 2016-03-31 |
$19.66B |
$15.03B |
1.31 |
| 2015-12-31 |
$20.98B |
$14.59B |
1.44 |
| 2015-09-30 |
$21.06B |
$15.24B |
1.38 |
| 2015-06-30 |
$21.33B |
$14.71B |
1.45 |
| 2015-03-31 |
$20.71B |
$14.95B |
1.39 |
| 2014-12-31 |
$20.92B |
$15.39B |
1.36 |
| 2014-09-30 |
$16.97B |
$17.68B |
0.96 |
| 2014-06-30 |
$17.02B |
$18.00B |
0.95 |
| 2014-03-31 |
$16.41B |
$18.35B |
0.89 |
| 2013-12-31 |
$17.61B |
$17.64B |
1.00 |
| 2013-09-30 |
$17.07B |
$16.90B |
1.01 |
| 2013-06-30 |
$17.99B |
$15.24B |
1.18 |
| 2013-03-31 |
$17.35B |
$14.96B |
1.16 |
| 2012-12-31 |
$19.63B |
$14.77B |
1.33 |
| 2012-09-30 |
$18.26B |
$16.06B |
1.14 |
| 2012-06-30 |
$17.51B |
$14.31B |
1.22 |
| 2012-03-31 |
$17.42B |
$14.82B |
1.18 |
| 2011-12-31 |
$20.12B |
$13.54B |
1.49 |
| 2011-09-30 |
$17.98B |
$15.06B |
1.19 |
| 2011-06-30 |
$18.50B |
$14.28B |
1.30 |
| 2011-03-31 |
$17.76B |
$13.93B |
1.28 |
| 2010-12-31 |
$18.59B |
$12.41B |
1.50 |
| 2010-09-30 |
$17.50B |
$12.41B |
1.41 |
| 2010-06-30 |
$17.49B |
$10.24B |
1.71 |
| 2010-03-31 |
$16.74B |
$10.46B |
1.60 |
| 2009-12-31 |
$17.94B |
$9.53B |
1.88 |
| 2009-09-30 |
$17.22B |
$9.91B |
1.74 |
| 2009-06-30 |
$18.37B |
$8.56B |
2.15 |
| 2009-03-31 |
$18.87B |
$7.73B |
2.44 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$719.145B |
$34.124B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
